Astellas Accused Of Delaying Generic Drug Approval

Law360, New York (September 14, 2011, 9:50 PM EDT) -- Astellas Pharma US Inc. was hit with a putative class action by a union benefit fund Wednesday in Massachusetts federal court for allegedly keeping a generic version of its immune-suppressing drug off the market and jacking up indirect purchasers' costs.

The New Mexico United Food and Commercial Workers Union's and Employers' Health and Welfare Trust Fund said Astellas has abused the generic drug application system to keep a cheaper rival of its Prograf drug from getting approved. The fund cited Astellas' September 2007 citizen petition to...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.